Effects of β-site amyloid precursor protein-cleaving enzyme-1 inhibitors on their protein levels

Takeaway

  • While β-site amyloid precursor protein-cleaving enzyme-1 (BACE1) inhibitors decrease amyloid-β levels, they also increase BACE1 protein levels by preventing degradation, which may be the reason they have not resulted in cognitive improvements in people with Alzheimer’s disease (AD).

Why this matters

  • Development of BACE1 inhibitors has been halted in clinical trials because they have failed to prevent cognitive decline in people with AD.

  • It is important to study BACE1 inhibitor action to understand why this investigational class is not effective and possibly improve potential therapies.